Covid-19 Impact on Global Pre-Implantation Genetic Diagnosis (PGD) Market Size, Status and Forecast 2020-2026

Pre-Implantation Genetic Diagnosis (PGD) is the genetic profiling of embryos prior to implantation (as a form of embryo profiling), and sometimes even of oocytes prior to fertilization.
When used to screen for a specific genetic disease, PGD main advantage is that it avoids selective abortion, as the method makes it highly likely that the baby will be free of the disease under consideration. PGD thus is an adjunct to assisted reproductive technology, and requires in vitro fertilization (IVF) to obtain oocytes or embryos for evaluation. Embryos are generally obtained through blastomere or blastocyst biopsy.

Market Analysis and Insights: Global Pre-Implantation Genetic Diagnosis (PGD) Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Pre-Implantation Genetic Diagnosis (PGD) market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Pre-Implantation Genetic Diagnosis (PGD) industry.
Based on our recent survey, we have several different scenarios about the Pre-Implantation Genetic Diagnosis (PGD) YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Pre-Implantation Genetic Diagnosis (PGD) will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

Global Pre-Implantation Genetic Diagnosis (PGD) Scope and Market Size
Pre-Implantation Genetic Diagnosis (PGD) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pre-Implantation Genetic Diagnosis (PGD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Pre-Implantation Genetic Diagnosis (PGD) market is segmented into Chromosomal Abnormalities, X-linked Diseases, Freeze Embryo Testing, Aneuploidy Screening, HLA, Others, etc.
Segment by Application, the Pre-Implantation Genetic Diagnosis (PGD) market is segmented into Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease, Others, etc.

Regional and Country-level Analysis
The Pre-Implantation Genetic Diagnosis (PGD) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Pre-Implantation Genetic Diagnosis (PGD) market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Pre-Implantation Genetic Diagnosis (PGD) Market Share Analysis
Pre-Implantation Genetic Diagnosis (PGD) market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Pre-Implantation Genetic Diagnosis (PGD) business, the date to enter into the Pre-Implantation Genetic Diagnosis (PGD) market, Pre-Implantation Genetic Diagnosis (PGD) product introduction, recent developments, etc.
The major vendors include Roche, Genea Limited, Quest Diagnostics, Illumina, Inc., Natera, Inc., Cooper Medical, Inc., LabCorp, California Pacific Medical Center (CPMC), Thermo Fisher Scientific Inc., IGENOMIX, Reproductive Genetic Innovations, CombiMatrix, etc.